MK-7262

MK-7262 is an investigational oral small molecule inhibitor developed by Merck & Co. (known as MSD outside the U.S. and Canada) for the treatment of elevated lipoprotein(a) [Lp(a)]. Elevated Lp(a) is a genetically determined, independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. Unlike injectable RNA-based therapies such as antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs) that target the LPA gene, MK-7262 is an orally bioavailable agent. It is designed to lower plasma Lp(a) levels by disrupting the assembly of the Lp(a) particle, likely by binding to apolipoprotein(a). MK-7262 is currently being evaluated in Phase 2 clinical trials both as a monotherapy and in combination with enlicitide decanoate (MK-0616), Merck's oral PCSK9 inhibitor, to assess its efficacy and safety in adults with elevated Lp(a).